Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Underlying trends for Hikma point to upside risks, says Citi » 12:46
01/05/21
01/05
12:46
01/05/21
12:46
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Citi analyst Peter…

Citi analyst Peter Verdult reiterated a Buy rating and GBp 3,030 price target on Hikma Pharmaceuticals (HKMPF), saying that November Iqvia (IQV) data points to trends towards, and above, the upper end of fiscal 2020 guidance. The analyst added that underlying trends point to upside risks.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

11/24/20 JPMorgan
Hikma Pharmaceuticals price target raised to 3,000 GBp from 2,400 GBp at JPMorgan
09/22/20 Morgan Stanley
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley
09/22/20 Morgan Stanley
Hikma downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/20 Goldman Sachs
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
Hot Stocks
Hikma Pharmaceuticals launches generic Advair Diskus following FDA approval » 16:32
12/17/20
12/17
16:32
12/17/20
16:32
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$37.33 /

+0.45 (+1.22%)

Hikma Pharmaceuticals…

Hikma Pharmaceuticals (HKMPF) announced it has received FDA approval for and launched its generic version of GlaxoSmithKline's (GSK) Advair Diskus, 100mcg/50mcg and 250mcg/50mcg doses in the U.S. According to IQVIA, U.S. sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2B in the 12 months ending September 2020.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.33 /

+0.45 (+1.22%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

11/24/20 JPMorgan
Hikma Pharmaceuticals price target raised to 3,000 GBp from 2,400 GBp at JPMorgan
09/22/20 Morgan Stanley
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley
09/22/20 Morgan Stanley
Hikma downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/20 Goldman Sachs
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
GSK GlaxoSmithKline
$37.33 /

+0.45 (+1.22%)

12/08/20 JPMorgan
GlaxoSmithKline price target lowered to 1,500 GBp from 1,650 GBp at JPMorgan
12/03/20
Fly Intel: Top five analyst downgrades
12/03/20 UBS
GlaxoSmithKline downgraded to Neutral from Buy at UBS
11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
GSK GlaxoSmithKline
$37.33 /

+0.45 (+1.22%)

GSK GlaxoSmithKline
$37.33 /

+0.45 (+1.22%)

GSK GlaxoSmithKline
$37.33 /

+0.45 (+1.22%)

GSK GlaxoSmithKline
$37.33 /

+0.45 (+1.22%)

Over a month ago
Recommendations
Hikma Pharmaceuticals price target raised to 3,000 GBp from 2,400 GBp at JPMorgan » 13:07
11/24/20
11/24
13:07
11/24/20
13:07
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

JPMorgan analyst James…

JPMorgan analyst James Gordon raised the firm's price target on Hikma Pharmaceuticals to 3,000 GBp from 2,400 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/22/20 Morgan Stanley
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley
09/22/20 Morgan Stanley
Hikma downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/20 Goldman Sachs
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
Hot Stocks
Hikma Pharmaceuticals launches Icosapent Ethyl capsules in the U.S. » 11:30
11/05/20
11/05
11:30
11/05/20
11:30
AMRN

Amarin

$4.74 /

-0.25 (-5.01%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Hikma Pharmaceuticals…

Hikma Pharmaceuticals (HKMPF) has launched Icosapent Ethyl Capsules, 1gm, in the US through its US affiliate, Hikma Pharmaceuticals USA Inc. Following an earlier than expected favorable court ruling, Hikma has accelerated the launch of its Icosapent Ethyl Capsules in order to quickly provide patients with access to this important medicine. Initially, Hikma will be releasing limited quantities to ensure a consistent supply for customers. The company is working to scale up manufacturing and increase availability as soon as possible. "Hikma's launch of this important medicine for US patients and healthcare providers once again underscores our ability to put better health, within reach, every day for millions of people who rely on our medicines," said Brian Hoffmann, President of Hikma Generics. "Today's launch demonstrates Hikma's ability to successfully challenge patents and launch complex products, bringing greater value to our customers and patients." Hikma's product is not approved for any other indication for the reference listed drug VASCEPA (AMRN).

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$4.74 /

-0.25 (-5.01%)

AMRN Amarin
$4.74 /

-0.25 (-5.01%)

10/26/20 Piper Sandler
Piper says Amarin presentations add 'layers of compelling evidence' for Vascepa
10/15/20 Piper Sandler
Analysis of Amarin's Vascepa to drive increased market share, says Piper Sandler
10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/05/20 Citi
GSK, Teva appeals court ruling could benefit Amarin, says Citi
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/22/20 Morgan Stanley
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley
09/22/20 Morgan Stanley
Hikma downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/20 Goldman Sachs
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
AMRN Amarin
$4.74 /

-0.25 (-5.01%)

AMRN Amarin
$4.74 /

-0.25 (-5.01%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$4.74 /

-0.25 (-5.01%)

AMRN Amarin
$4.74 /

-0.25 (-5.01%)

Over a quarter ago
Downgrade
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley » 06:32
09/22/20
09/22
06:32
09/22/20
06:32
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Morgan Stanley analyst Thibault Boutherin downgraded Hikma Pharmaceuticals to Equal Weight from Overweight with a price target of 2,600 GBp, down from 2,700 GBp, noting that expectations for Hikma have been raised.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/22/20 Morgan Stanley
Hikma downgraded to Equal Weight from Overweight at Morgan Stanley
09/08/20 Goldman Sachs
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
09/04/20 Barclays
Hikma Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

Downgrade
Hikma downgraded to Equal Weight from Overweight at Morgan Stanley » 05:18
09/22/20
09/22
05:18
09/22/20
05:18
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Morgan Stanley analyst Thibault Boutherin downgraded Hikma Pharmaceuticals to Equal Weight from Overweight with a 2,700 GBp price target.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/08/20 Goldman Sachs
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
09/04/20 Barclays
Hikma Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
09/03/20 Oppenheimer
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

Upgrade
Hikma Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs » 05:13
09/08/20
09/08
05:13
09/08/20
05:13
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Krishna Arikatla upgraded Hikma Pharmaceuticals to Buy from Neutral with a price target of 3,115 GBp, up from 2,600 GBp. Hikma shares can continue to outperform, as potential launches of Advair and Vascepa provide upside risk to consensus estimates, Arikatla tells investors in a research note. The analyst believes consensus estimates are underappreciating the bottom line contribution from these two launches, especially for Advair.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
09/04/20 Barclays
Hikma Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
09/03/20 Oppenheimer
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
08/14/20 Barclays
Hikma price target raised to 2,350 GBp from 2,200 GBp at Barclays
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

Recommendations
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity » 07:09
09/04/20
09/04
07:09
09/04/20
07:09
AMRN

Amarin

$4.58 /

-0.455 (-9.05%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Choi lowered the firm's price target on Amarin (AMRN) to $8 from $9 and keeps a Neutral rating on the shares after reducing expectations for sales of Vascepa to reflect the court's negative appeal decision. The analyst expects at least one generic product to be launched imminently, potentially as soon as year-end. Hikma Pharmaceuticals (HKMPF) management has disclosed that they are comfortable with their ability to ramp supply and to initiate a launch following the court's decision, Choi tells investors in a research note. While it remains to be seen how Amarin will contend with the entry of generics products into the market, management recently emphasized its willingness to compete on price, adds the analyst. Choi, however, continues to view the market opportunity for Vascepa in Europe as "significant" at $1.3B in peak sales, and he expects investor focus to now shift to Amarin's opportunities outside the U.S.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$4.58 /

-0.455 (-9.05%)

AMRN Amarin
$4.58 /

-0.455 (-9.05%)

09/03/20 Stifel
Amarin price target lowered to $5 from $8 at Stifel
09/03/20 Piper Sandler
Amarin focus shifts to EU opportunity after patent ruling, says Piper Sandler
09/03/20 Northland
Amarin shares have downside to $3 on patent loss, says Northland
09/03/20 Oppenheimer
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/04/20 Barclays
Hikma Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
08/14/20 Barclays
Hikma price target raised to 2,350 GBp from 2,200 GBp at Barclays
07/07/20 Morgan Stanley
Hikma upgraded to Overweight from Equal Weight at Morgan Stanley
AMRN Amarin
$4.58 /

-0.455 (-9.05%)

AMRN Amarin
$4.58 /

-0.455 (-9.05%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$4.58 /

-0.455 (-9.05%)

AMRN Amarin
$4.58 /

-0.455 (-9.05%)

Upgrade
Hikma Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays » 05:11
09/04/20
09/04
05:11
09/04/20
05:11
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Barclays analyst Emily…

Barclays analyst Emily Field upgraded Hikma Pharmaceuticals to Overweight from Equal Weight with a 2,800 GBp price target. The analyst has a high degree of confidence in adding Vascepa to the model following yesterday's court ruling. The decision on Vascepa came well ahead of schedule and the product should be significantly accretive for 2020 and 2021 earnings, Field tells investors in a research note.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/03/20 Oppenheimer
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
08/14/20 Barclays
Hikma price target raised to 2,350 GBp from 2,200 GBp at Barclays
07/07/20 Morgan Stanley
Hikma upgraded to Overweight from Equal Weight at Morgan Stanley
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

Hot Stocks
Hikma says 'working towards a launch' of generic version of Amarin's Vascepa  10:20
09/03/20
09/03
10:20
09/03/20
10:20
HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, AMRN

Amarin

$4.92 /

-0.11 (-2.19%)

 
ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$4.92 /

-0.11 (-2.19%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

09/03/20 Oppenheimer
Opco 'more skeptical' on Amarin patent win after 20 minute court hearing
08/14/20 Barclays
Hikma price target raised to 2,350 GBp from 2,200 GBp at Barclays
07/07/20 Morgan Stanley
Hikma upgraded to Overweight from Equal Weight at Morgan Stanley
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$4.92 /

-0.11 (-2.19%)

09/03/20 Northland
Amarin shares have downside to $3 on patent loss, says Northland
09/02/20 Goldman Sachs
Oral arguments incrementally negative for Amarin, says Goldman Sachs
09/02/20 Piper Sandler
Piper says Amarin patent battle 'didn't go as planned,' but war 'far from over'
AMRN Amarin
$4.92 /

-0.11 (-2.19%)

AMRN Amarin
$4.92 /

-0.11 (-2.19%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$4.92 /

-0.11 (-2.19%)

AMRN Amarin
$4.92 /

-0.11 (-2.19%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.